WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoCHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias
Ver el documentoCYCLOOXYGENASE-2 INHIBITORS - Plans to review all medicines in this class
Ver el documentoETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis
Ver el documentoHERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada
Ver el documentoINFLUENZA VIRUS VACCINE - Interactions with drugs
Ver el documentoMEDROXY PROGESTERONE - Effect on bone mineral density
Ver el documentoPAMIDRONATE DISODIUM, ZOLEDRONIC ACID - Spontaneous reports of osteonecrosis of the jaw
Ver el documentoSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - ADRAC reviews use in children and adolescents
Ver el documentoTERBINAFINE - Reports of blood dyscrasias
Ver el documentoTRICYCLIC ANTIDEPRESSANTS - Overdose risk
Ver el documentoFEATURE
 

INFLUENZA VIRUS VACCINE - Interactions with drugs

New Zealand. In a recent Prescriber Update article posted on the New Zealand Medsafe website, prescribers are advised to be alert for signs of toxicity following influenza vaccination in patients receiving antiepileptic drugs or warfarin. Medsafe notes that, in addition to published reports of warfarin, phenytoin and theophylline toxicity following influenza vaccination, a report of carbamazepine toxicity has been received by the Australian Adverse Drug Reactions Advisory Committee, and a report of elevated International Normalized Ratio (INR) in a patient receiving warfarin has been received by the Centre for Adverse Reactions Monitoring, both following influenza vaccination. It is suggested that inhibition of cytochrome P450 3A4 may be involved in these interactions, and prescribers are advised to watch for toxicity in patients receiving drugs metabolized by this enzyme.

Reference:

Prescriber Update 25(2), November 2004.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013